Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial.

Date publication

août 2023

Journal

EClinicalMedicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BILGER Karin , Dr DAGUINDAU Etienne

Tous les auteurs :
Malard F, Loschi M, Huynh A, Cluzeau T, Guenounou S, Legrand F, Magro L, Orvain C, Charbonnier A, Panz-Klapuch M, Desmier D, Mear JB, Cornillon J, Robin C, Daguindau E, Bilger K, Vehreschild MJGT, Chevallier P, Labussière-Wallet H, Mediavilla C, Couturier MA, Bulabois CE, Camus V, Chantepie S, Ceballos P, Gaugler B, Holler E, Doré J, Prestat E, Gasc C, Plantamura E, Mohty M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37654670

Résumé

Failure of gastrointestinal acute graft--host disease (GI-aGvHD) to respond to steroid therapy is associated with limited further therapeutic options. We aimed to assess the safety and efficacy of the first-in-human use of the pooled allogeneic faecal microbiota, MaaT013, for the treatment of steroid-refractory GI-aGvHD.

Mots clés

Acute graft-versus-host disease, Allogeneic haematopoietic cell transplantation, Faecal microbiota transplantation, Microbiota, Prospective study

Référence

EClinicalMedicine. 2023 08;62:102111